Many patients diagnosed with localized prostate cancer will undergo primary therapy with radical prostatectomy. An estimated 25% to 40% of such patients will eventually experience biochemical recurrence (BCR) by 10 years after primary therapy.1,2 Postprostatectomy patients with BCR may be offered salvage radiation therapy if they have a rising detectable prostate-specific antigen (PSA) level and no radiographic evidence of nodal or metastatic disease. At the American Society for Radiation Oncology (ASTRO) 2022 meeting, several authors presented abstracts on the topic of postprostatectomy radiation that are worth reviewing. ...
GU Oncology Now Journal
A publication highlighting original articles and interviews.
Advertisement
Articles from the Latest Issue
Upfront cytoreductive nephrectomy for patients with MRCC with immune checkpoint inhibitors or targeted therapy is examined.
Dr. Daniel Tennenbaum interviews Dr. Catherine H. Marshall on trends in managing advanced and metastatic prostate cancer.
Dr. Yasser Ged describes his GU oncology career that has spanned over three continents.
The Uromigos: Live & Unplugged event incorporated presentations and discussions in the field of urologic malignancies.
A detail of the analgesic modalities available for treatment of patients undergoing minimally-invasive urologic surgery.
According to a recent study published in The Lancet Oncology, radiation may offer safety and long-term efficacy for RCC.
Advertisement
Browse Our Past Issues
Articles from the December 2022 issue of the GU Oncology Now Journal
Articles from the November 2022 issue of the GU Oncology Now Journal
Articles from the October 2022 issue of the GU Oncology Now Journal
Articles from the September 2022 issue of the GU Oncology Now Journal
Articles from the August 2022 issue of the GU Oncology Now Journal
Articles from the July 2022 issue of the GU Oncology Now Journal
Articles from the June 2022 issue of the GU Oncology Now Journal
Articles from the May 2022 issue of the GU Oncology Now Journal
Articles from the April 2022 issue of the GU Oncology Now Journal
Articles from the March 2022 issue of the GU Oncology Now Journal
Articles from the February 2022 issue of the GU Oncology Now Journal
Articles from the January 2022 issue of the GU Oncology Now Journal
Articles from Issue 10 of the GU Oncology Now Journal
Articles from Issue 9 of the GU Oncology Now Journal
Articles from Issue 8 of the GU Oncology Now Journal
Articles from Issue 7 of the GU Oncology Now Journal
Articles from Issue 6 of the GU Oncology Now Journal
Articles from Issue 5 of the GU Oncology Now Journal
Articles from Issue 4 of the GU Oncology Now Journal
Articles from Issue 3 of the GU Oncology Now Journal
Articles from Issue 2 of the GU Oncology Now Journal
Articles from Issue 1 of the GU Oncology Now Journal
Advertisement
Advertisement
Editorial Advisory Board
Brian Rini, MD, FASCOEditor | Chief of Clinical Trials at Vanderbilt-Ingram Cancer Center
Thomas Powles, MBBS, MRCP, MDEditor | Director, Barts Cancer Centre at St. Bartholomew's Hospital
Catherine H. Marshall, MD, MPHEditor | Assistant Professor of Oncology at the Johns Hopkins University School of Medicine
Jérémie Calais, MD, PhDEditor | Director of the Theranostics and Clinical Research Programs at the University of California, Los Angeles
Akhil Abraham Saji, MDEditor | Fellow at the University of Southern California
David Ambinder, MDEditor | Urology Resident at New York Medical College/Westchester Medical Center
